Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

The potential of glycomics as prognostic biomarkers in liver disease and liver transplantation.

Verhelst X, Geerts A, Callewaert N, Van Vlierberghe H.

Acta Gastroenterol Belg. 2019 Apr-Jun;82(2):309-313. Review.

PMID:
31314193
2.

Validation, Clinical Utility and Limitations of the Amsterdam-Oxford Model for Primary Sclerosing Cholangitis.

Goet JC, Floreani A, Verhelst X, Cazzagon N, Perini L, Lammers WJ, de Vries AC, van der Meer AJ, van Buuren HR, Hansen BE.

J Hepatol. 2019 Jul 3. pii: S0168-8278(19)30384-8. doi: 10.1016/j.jhep.2019.06.012. [Epub ahead of print]

PMID:
31278949
3.

Screening for hepatitis C viral infection in a non-urban primary care facility in Flanders.

Verhelst X, Devolder G, De Wilde M, Goderis L, De Bel A, Spillebeen E, Geerts A, Derese A, Van Vlierberghe H.

Acta Gastroenterol Belg. 2019 Jan-Mar;82(1):99-100. No abstract available.

PMID:
30888763
4.

Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.

Cheung AC, Lammers WJ, Murillo Perez CF, van Buuren HR, Gulamhusein A, Trivedi PJ, Lazaridis KN, Ponsioen CY, Floreani A, Hirschfield GM, Corpechot C, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Nevens F, Thorburn D, Mason AL, Carbone M, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Lindor KD, Lleo A, Poupon R, Janssen HL, Hansen BE; Global PBC Study Group.

Clin Gastroenterol Hepatol. 2019 Jan 4. pii: S1542-3565(19)30001-1. doi: 10.1016/j.cgh.2018.12.028. [Epub ahead of print]

PMID:
30616022
5.

Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide.

Piano S, Singh V, Caraceni P, Maiwall R, Alessandria C, Fernandez J, Soares EC, Kim DJ, Kim SE, Marino M, Vorobioff J, Barea RCR, Merli M, Elkrief L, Vargas V, Krag A, Singh SP, Lesmana LA, Toledo C, Marciano S, Verhelst X, Wong F, Intagliata N, Rabinowich L, Colombato L, Kim SG, Gerbes A, Durand F, Roblero JP, Bhamidimarri KR, Boyer TD, Maevskaya M, Fassio E, Kim HS, Hwang JS, Gines P, Gadano A, Sarin SK, Angeli P; International Club of Ascites Global Study Group.

Gastroenterology. 2019 Apr;156(5):1368-1380.e10. doi: 10.1053/j.gastro.2018.12.005. Epub 2018 Dec 13.

PMID:
30552895
6.

Outcome of liver transplantation for hepatopulmonary syndrome: a Eurotransplant experience.

Raevens S, Rogiers X, Geerts A, Verhelst X, Samuel U, van Rosmalen M, Berlakovich G, Delwaide J, Detry O, Lehner F, Mittler J, Nadalin S, Nevens F, Pirenne J, Saner F, Schneeberger S, Stippel D, Turk JM, Zoltan M, Troisi RI, Van Vlierberghe H, Colle I.

Eur Respir J. 2019 Jan 31;53(2). pii: 1801096. doi: 10.1183/13993003.01096-2018. Print 2019 Feb. No abstract available.

7.

Secondary Adrenal Insufficiency after Treatment with Budesonide for Autoimmune Hepatitis.

De Maeyer F, Lapauw B, Hoorens A, Geerts A, Van Vlierberghe H, Verhelst X.

Case Rep Gastroenterol. 2018 Oct 2;12(3):597-601. doi: 10.1159/000492204. eCollection 2018 Sep-Dec.

8.

Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival.

Montano-Loza AJ, Hansen BE, Corpechot C, Roccarina D, Thorburn D, Trivedi P, Hirschfield G, McDowell P, Poupon R, Dumortier J, Bosch A, Giostria E, Conti F, Parés A, Reig A, Floreani A, Russo FP, Goet JC, Harms MH, van Buuren H, Van den Ende N, Nevens F, Verhelst X, Donato MF, Malinverno F, Ebadi M, Mason AL; Global PBC Study Group.

Gastroenterology. 2019 Jan;156(1):96-107.e1. doi: 10.1053/j.gastro.2018.10.001. Epub 2018 Oct 6.

PMID:
30296431
9.

Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease.

Lefere S, Van de Velde F, Hoorens A, Raevens S, Van Campenhout S, Vandierendonck A, Neyt S, Vandeghinste B, Vanhove C, Debbaut C, Verhelst X, Van Dorpe J, Van Steenkiste C, Casteleyn C, Lapauw B, Van Vlierberghe H, Geerts A, Devisscher L.

Hepatology. 2019 Mar;69(3):1087-1104. doi: 10.1002/hep.30294. Epub 2019 Feb 12.

PMID:
30259536
10.

Endoglycosidase S Enables a Highly Simplified Clinical Chemistry Procedure for Direct Assessment of Serum IgG Undergalactosylation in Chronic Inflammatory Disease.

Vanderschaeghe D, Meuris L, Raes T, Grootaert H, Van Hecke A, Verhelst X, Van de Velde F, Lapauw B, Van Vlierberghe H, Callewaert N.

Mol Cell Proteomics. 2018 Dec;17(12):2508-2517. doi: 10.1074/mcp.TIR118.000740. Epub 2018 Sep 6.

PMID:
30190373
11.

Clinical burden of hepatitis E virus infection in a tertiary care center in Flanders, Belgium.

Cattoir L, Van Hoecke F, Van Maerken T, Nys E, Ryckaert I, De Boulle M, Geerts A, Verhelst X, Colle I, Hutse V, Suin V, Wautier M, Van Gucht S, Van Vlierberghe H, Padalko E.

J Clin Virol. 2018 Jun;103:8-11. doi: 10.1016/j.jcv.2018.03.004. Epub 2018 Mar 19.

PMID:
29602096
12.

Severe Hepatic and Pulmonary Involvement in Rendu-Osler-Weber Syndrome.

Verhelst X, Geerts A, Van Vlierberghe H, Smeets P, Lecluyse C.

Case Rep Gastroenterol. 2018 Jan 17;12(1):13-18. doi: 10.1159/000486189. eCollection 2018 Jan-Apr.

13.

Glycome Patterns of Perfusate in Livers Before Transplantation Associate With Primary Nonfunction.

Verhelst X, Geerts A, Jochmans I, Vanderschaeghe D, Paradissis A, Vanlander A, Berrevoet F, Dahlqvist G, Nevens F, Pirenne J, Rogiers X, Callewaert N, Troisi RI, Van Vlierberghe H.

Gastroenterology. 2018 Apr;154(5):1361-1368. doi: 10.1053/j.gastro.2017.12.027. Epub 2018 Jan 6.

PMID:
29309776
14.

Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.

Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, Battezzati PM, Nevens F, Lindor KD, Floreani A, Ponsioen CY, Mayo MJ, Dalekos GN, Bruns T, Parés A, Mason AL, Verhelst X, Kowdley KV, Goet JC, Hirschfield GM, Hansen BE, van Buuren HR; Global PBC Study Group.

Am J Gastroenterol. 2018 Feb;113(2):254-264. doi: 10.1038/ajg.2017.440. Epub 2017 Dec 12.

PMID:
29231188
15.

Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history.

Murillo Perez CF, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, Carbone M, Mason A, Corpechot C, Invernizzi P, Mayo MJ, Battezzati PM, Floreani A, Pares A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Thorburn D, Hirschfield G, LaRusso NF, Lindor KD, Zachou K, Poupon R, Trivedi PJ, Verhelst X, Janssen HLA, Hansen BE; GLOBAL PBC Study Group.

Hepatology. 2018 May;67(5):1920-1930. doi: 10.1002/hep.29717. Epub 2018 Apr 6.

16.

Non-alcoholic steatohepatitis induces transient changes within the liver macrophage pool.

Devisscher L, Scott CL, Lefere S, Raevens S, Bogaerts E, Paridaens A, Verhelst X, Geerts A, Guilliams M, Van Vlierberghe H.

Cell Immunol. 2017 Dec;322:74-83. doi: 10.1016/j.cellimm.2017.10.006. Epub 2017 Oct 16.

PMID:
29111158
17.

Placental growth factor inhibition targets pulmonary angiogenesis and represents a therapy for hepatopulmonary syndrome in mice.

Raevens S, Geerts A, Paridaens A, Lefere S, Verhelst X, Hoorens A, Van Dorpe J, Maes T, Bracke KR, Casteleyn C, Jonckx B, Horvatits T, Fuhrmann V, Van Vlierberghe H, Van Steenkiste C, Devisscher L, Colle I.

Hepatology. 2018 Aug;68(2):634-651. doi: 10.1002/hep.29579. Epub 2018 May 11.

PMID:
29023811
18.

Hepatitis E virus serology and PCR: does the methodology matter?

Cattoir L, Van Hoecke F, Van Maerken T, Nys E, Ryckaert I, De Boulle M, Geerts A, Verhelst X, Colle I, Hutse V, Suin V, Wautier M, Van Gucht S, Van Vlierberghe H, Padalko E.

Arch Virol. 2017 Sep;162(9):2625-2632. doi: 10.1007/s00705-017-3395-0. Epub 2017 May 18.

PMID:
28523520
19.

Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease.

Lefere S, Van de Velde F, Devisscher L, Bekaert M, Raevens S, Verhelst X, Van Nieuwenhove Y, Praet M, Hoorens A, Van Steenkiste C, Van Vlierberghe H, Lapauw B, Geerts A.

Int J Obes (Lond). 2017 Aug;41(8):1207-1213. doi: 10.1038/ijo.2017.102. Epub 2017 May 2.

PMID:
28461687
20.

Modulation of the Unfolded Protein Response by Tauroursodeoxycholic Acid Counteracts Apoptotic Cell Death and Fibrosis in a Mouse Model for Secondary Biliary Liver Fibrosis.

Paridaens A, Raevens S, Devisscher L, Bogaerts E, Verhelst X, Hoorens A, Van Vlierberghe H, van Grunsven LA, Geerts A, Colle I.

Int J Mol Sci. 2017 Jan 20;18(1). pii: E214. doi: 10.3390/ijms18010214.

21.

Refractory subacute steatohepatitis after biliopancreatic diversion.

Lefere S, Hoorens A, Raevens S, Troisi R, Verhelst X, Van Vlierberghe H, Geerts A.

Hepatology. 2017 Jul;66(1):289-291. doi: 10.1002/hep.29038. Epub 2017 May 9. No abstract available.

PMID:
28073162
22.

A Glycomics-Based Test Predicts the Development of Hepatocellular Carcinoma in Cirrhosis.

Verhelst X, Vanderschaeghe D, Castéra L, Raes T, Geerts A, Francoz C, Colman R, Durand F, Callewaert N, Van Vlierberghe H.

Clin Cancer Res. 2017 Jun 1;23(11):2750-2758. doi: 10.1158/1078-0432.CCR-16-1500. Epub 2016 Dec 16.

23.

Combination of tauroursodeoxycholic acid and N-acetylcysteine exceeds standard treatment for acetaminophen intoxication.

Paridaens A, Raevens S, Colle I, Bogaerts E, Vandewynckel YP, Verhelst X, Hoorens A, van Grunsven LA, Van Vlierberghe H, Geerts A, Devisscher L.

Liver Int. 2017 May;37(5):748-756. doi: 10.1111/liv.13261. Epub 2016 Oct 25.

PMID:
27706903
24.

Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity.

Bekaert M, Ouwens DM, Hörbelt T, Van de Velde F, Fahlbusch P, Herzfeld de Wiza D, Van Nieuwenhove Y, Calders P, Praet M, Hoorens A, Geerts A, Verhelst X, Kaufman JM, Lapauw B.

Obesity (Silver Spring). 2016 Dec;24(12):2544-2552. doi: 10.1002/oby.21674. Epub 2016 Oct 21.

25.

Comments on the impact of genotyping method on the subtype distribution of HCV genotype 1.

Van den Borre C, Schuermans W, Van Vlierberghe H, Geerts A, Verhelst X, Padalko E.

J Clin Virol. 2016 Oct;83:54-5. doi: 10.1016/j.jcv.2016.08.291. Epub 2016 Aug 20. No abstract available.

PMID:
27591556
26.

Heads or Tails: Genotyping of Hepatitis C Virus Concerning the 2k/1b Circulating Recombinant Form.

Schuermans W, Orlent H, Desombere I, Descheemaeker P, Van Vlierberghe H, Geerts A, Verhelst X, Reynders M, Padalko E.

Int J Mol Sci. 2016 Aug 23;17(9). pii: E1384. doi: 10.3390/ijms17091384.

27.

Quality of life after liver transplantation: State of the art.

Onghena L, Develtere W, Poppe C, Geerts A, Troisi R, Vanlander A, Berrevoet F, Rogiers X, Van Vlierberghe H, Verhelst X.

World J Hepatol. 2016 Jun 28;8(18):749-56. doi: 10.4254/wjh.v8.i18.749. Review.

28.

Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma.

Vandewynckel YP, Coucke C, Laukens D, Devisscher L, Paridaens A, Bogaerts E, Vandierendonck A, Raevens S, Verhelst X, Van Steenkiste C, Libbrecht L, Geerts A, Van Vlierberghe H.

Oncotarget. 2016 Jun 7;7(23):34988-5000. doi: 10.18632/oncotarget.9222.

29.

Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease.

Lefere S, Van Steenkiste C, Verhelst X, Van Vlierberghe H, Devisscher L, Geerts A.

Cell Mol Life Sci. 2016 Sep;73(18):3419-31. doi: 10.1007/s00018-016-2222-1. Epub 2016 Apr 18. Review.

PMID:
27091156
30.

The role of macrophages in obesity-driven chronic liver disease.

Devisscher L, Verhelst X, Colle I, Van Vlierberghe H, Geerts A.

J Leukoc Biol. 2016 May;99(5):693-8. doi: 10.1189/jlb.5RU0116-016R. Epub 2016 Mar 2. Review.

PMID:
26936934
31.

Successful Treatment of HCV-associated B-Cell Non-Hodgkin Lymphomas With Direct-acting Antiviral Agents.

de Clerck F, Geerts A, Brochez L, Speeckaert R, Boterberg T, Van Vlierberghe H, Verhelst X.

J Clin Gastroenterol. 2016 May-Jun;50(5):438. doi: 10.1097/MCG.0000000000000506. No abstract available.

PMID:
26905607
32.

Longitudinal Transient Elastography Measurements Used in Follow-up for Patients with Cystic Fibrosis.

Van Biervliet S, Verdievel H, Vande Velde S, De Bruyne R, De Looze D, Verhelst X, Geerts A, Robberecht E, Van Vlierberghe H.

Ultrasound Med Biol. 2016 Apr;42(4):848-54. doi: 10.1016/j.ultrasmedbio.2015.11.011. Epub 2016 Jan 21.

PMID:
26806442
33.

Placental growth factor inhibition modulates the interplay between hypoxia and unfolded protein response in hepatocellular carcinoma.

Vandewynckel YP, Laukens D, Devisscher L, Bogaerts E, Paridaens A, Van den Bussche A, Raevens S, Verhelst X, Van Steenkiste C, Jonckx B, Libbrecht L, Geerts A, Carmeliet P, Van Vlierberghe H.

BMC Cancer. 2016 Jan 11;16:9. doi: 10.1186/s12885-015-1990-6.

34.

Effect of prolyl hydroxylase domain 2 haplodeficiency on liver progenitor cell characteristics in early mouse hepatocarcinogenesis.

Bogaerts E, Paridaens A, Verhelst X, Carmeliet P, Geerts A, Van Vlierberghe H, Devisscher L.

EXCLI J. 2016 Nov 11;15:687-698. doi: 10.17179/excli2016-607. eCollection 2016.

35.

Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review.

Bekaert M, Verhelst X, Geerts A, Lapauw B, Calders P.

Obes Rev. 2016 Jan;17(1):68-80. doi: 10.1111/obr.12333. Epub 2015 Nov 24. Review.

PMID:
26597657
36.

Tauroursodeoxycholic acid dampens oncogenic apoptosis induced by endoplasmic reticulum stress during hepatocarcinogen exposure.

Vandewynckel YP, Laukens D, Devisscher L, Paridaens A, Bogaerts E, Verhelst X, Van den Bussche A, Raevens S, Van Steenkiste C, Van Troys M, Ampe C, Descamps B, Vanhove C, Govaere O, Geerts A, Van Vlierberghe H.

Oncotarget. 2015 Sep 29;6(29):28011-25. doi: 10.18632/oncotarget.4377.

37.

IgG4-related cholangitis: Case report and literature review.

De Both A, Van Vlierberghe H, Geerts A, Libbrecht L, Verhelst X.

Acta Gastroenterol Belg. 2015 Jan-Mar;78(1):62-4.

PMID:
26118582
38.

Intramuscular hepatitis B immunoglobulins for reinfection control after liver transplantation: a cost-saving alternative.

Hulstaert E, Verhelst X, Geerts A, Van Vlierberghe H.

J Comp Eff Res. 2015 May;4(3):259-265. doi: 10.2217/cer.15.4. Epub 2015 May 8.

PMID:
25951856
39.

Time-dependent effect of hypoxia on tumor progression and liver progenitor cell markers in primary liver tumors.

Bogaerts E, Heindryckx F, Devisscher L, Paridaens A, Vandewynckel YP, Van den Bussche A, Verhelst X, Libbrecht L, van Grunsven LA, Geerts A, Van Vlierberghe H.

PLoS One. 2015 Mar 20;10(3):e0119555. doi: 10.1371/journal.pone.0119555. eCollection 2015.

40.

Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment.

Raevens S, Geerts A, Van Steenkiste C, Verhelst X, Van Vlierberghe H, Colle I.

Liver Int. 2015 Jun;35(6):1646-60. doi: 10.1111/liv.12791. Epub 2015 Feb 16. Review.

PMID:
25627425
41.

Modulation of the unfolded protein response impedes tumor cell adaptation to proteotoxic stress: a PERK for hepatocellular carcinoma therapy.

Vandewynckel YP, Laukens D, Bogaerts E, Paridaens A, Van den Bussche A, Verhelst X, Van Steenkiste C, Descamps B, Vanhove C, Libbrecht L, De Rycke R, Lambrecht BN, Geerts A, Janssens S, Van Vlierberghe H.

Hepatol Int. 2014 Oct 1;9(1):93-104. doi: 10.1007/s12072-014-9582-0. eCollection 2015 Jan.

42.

Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma.

Vandewynckel YP, Geerts A, Verhelst X, Van Vlierberghe H.

Clin Case Rep. 2014 Feb;2(1):4-6. doi: 10.1002/ccr3.34. Epub 2013 Dec 31.

43.

Cutaneous infection by Alternaria infectoria in a liver transplant recipient: a case report.

Coussens E, Rogge S, Haspeslagh M, Geerts A, Verhelst X, Van Vlierberghe H, Troisi RI, Colle I.

Acta Gastroenterol Belg. 2014 Jun;77(2):256-8.

PMID:
25090825
44.

Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent.

Vandewynckel YP, Laukens D, Geerts A, Vanhove C, Descamps B, Colle I, Devisscher L, Bogaerts E, Paridaens A, Verhelst X, Van Steenkiste C, Libbrecht L, Lambrecht BN, Janssens S, Van Vlierberghe H.

Eur J Gastroenterol Hepatol. 2014 Aug;26(8):861-70. doi: 10.1097/MEG.0000000000000066.

PMID:
24987823
45.

Pathophysiology and management of post resection liver failure.

Colle I, Verhelst X, Vanlander A, Geerts A, Van Vlierberghe H, Berrevoet F, Rogiers X, Troisi RI.

Acta Chir Belg. 2013 May-Jun;113(3):155-61. Review.

PMID:
24941709
46.

Role of angiogenic factors/cell adhesion markers in serum of cirrhotic patients with hepatopulmonary syndrome.

Raevens S, Coulon S, Van Steenkiste C, Colman R, Verhelst X, Van Vlierberghe H, Geerts A, Perkmann T, Horvatits T, Fuhrmann V, Colle I.

Liver Int. 2015 May;35(5):1499-507. doi: 10.1111/liv.12579. Epub 2014 May 17.

PMID:
24766195
47.

The paradox of the unfolded protein response in cancer.

Vandewynckel YP, Laukens D, Geerts A, Bogaerts E, Paridaens A, Verhelst X, Janssens S, Heindryckx F, Van Vlierberghe H.

Anticancer Res. 2013 Nov;33(11):4683-94. Review.

PMID:
24222102
48.

Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation.

Raevens S, De Pauw M, Reyntjens K, Geerts A, Verhelst X, Berrevoet F, Rogiers X, Troisi RI, Van Vlierberghe H, Colle I.

Eur J Gastroenterol Hepatol. 2013 Apr;25(4):495-502. doi: 10.1097/MEG.0b013e32835c504b.

PMID:
23242127
49.

Biomarkers for the diagnosis of acute cellular rejection in liver transplant recipients: A review.

Verhelst XP, Troisi RI, Colle I, Geerts A, van Vlierberghe H.

Hepatol Res. 2013 Feb;43(2):165-78. doi: 10.1111/hepr.12012. Epub 2012 Nov 27.

PMID:
23186289
50.

A case of emphysematous gastritis.

Verhelst X, Cabooter M, de Wilde V, Laukens P, Orlent H.

Endoscopy. 2012;44 Suppl 2 UCTN:E159. doi: 10.1055/s-0031-1291746. Epub 2012 May 23. No abstract available.

PMID:
22622720

Supplemental Content

Loading ...
Support Center